Danone (DN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
Q3 like-for-like sales grew 4.0%, with growth across all three geographic zones and categories.
2026 guidance was confirmed: like-for-like sales growth of 3%–5%, with recurring operating income growing faster than sales.
Financial highlights
Q3 sales were €7,233m, up 5.2% reported and 4.0% like-for-like.
9M sales were €21,176m, up 3.6% like-for-like and 2.9% reported.
Q3 reported sales growth included +1.5% currency, -0.5% scope, -0.1% IAS 29 and +0.4% hyperinflation.
Outlook and guidance
FY 2026 guidance remained 3%–5% like-for-like sales growth, with recurring operating income growing faster than sales, in line with mid-term ambition.
North America priorities include restoring customer service, strengthening execution and competitiveness, and advancing a broader innovation pipeline for 2027.
Specialized Nutrition emerging markets delivered double-digit growth in Latin America and Middle East Africa, and high-single-digit growth in the rest of APAC; resources are being reallocated to the region.
Latest events from Danone
- Global growth in protein, gut health, and plant-based drives resilience and margin expansion.DN
Barclays 19th Annual Global Consumer Conference - H1 2026 saw strong sales, margin gains, and portfolio expansion; 2026 guidance reaffirmed.DN
Q2 2026 - Growth driven by health trends, innovation, and digital transformation, with strong future outlook.DN
23rd annual dbAccess Global Consumer Conference - Q1 2026 delivered +2.7% LFL sales growth, but reported sales fell -2.0% on currency impacts.DN
Q1 2026 - 4.5% LFL sales growth, margin up 44bps, and strong cash flow despite currency and recall impacts.DN
Q4 2025 - Q3 2025 sales rose 4.8% LFL, driven by volume/mix and strong China, North Asia & Oceania growth.DN
Q3 2025 - 4.2% LFL sales growth, margin up 49 bps, EPS up 5.8%, and key acquisitions in H1 2025.DN
Q2 2025 - H1 2024 saw 4.0% LFL sales growth, margin expansion, strong cash flow, and portfolio actions.DN
Q2 2024 - Targets 3–5% sales growth and €3bn free cash flow by 2028, led by science and Medical Nutrition.DN
CME 2024